Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03420963
Recruitment Status : Recruiting
First Posted : February 2, 2018
Last Update Posted : May 20, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer [NK] cells) and also how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Drugs used in chemotherapy, such as cyclophosphamide and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NK cells together with cyclophosphamide and etoposide may work better in treating children and young adults with solid tumors.

Condition or disease Intervention/treatment Phase
Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation Recurrent Lip and Oral Cavity Carcinoma Recurrent Malignant Endocrine Neoplasm Recurrent Malignant Female Reproductive System Neoplasm Recurrent Malignant Male Reproductive System Neoplasm Recurrent Malignant Mesothelioma Recurrent Malignant Neoplasm of Multiple Primary Sites Recurrent Malignant Oral Neoplasm Recurrent Malignant Pharyngeal Neoplasm Recurrent Malignant Skin Neoplasm Recurrent Malignant Soft Tissue Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Malignant Thyroid Gland Neoplasm Recurrent Malignant Urinary System Neoplasm Recurrent Melanoma of the Skin Refractory Cutaneous Melanoma Refractory Malignant Bone Neoplasm Refractory Malignant Endocrine Neoplasm Refractory Malignant Female Reproductive System Neoplasm Refractory Malignant Male Reproductive System Neoplasm Refractory Malignant Mesothelioma Refractory Malignant Neoplasm of Multiple Primary Sites Refractory Malignant Oral Neoplasm Refractory Malignant Pharyngeal Neoplasm Refractory Malignant Skin Neoplasm Refractory Malignant Soft Tissue Neoplasm Refractory Malignant Solid Neoplasm Refractory Malignant Thyroid Gland Neoplasm Refractory Malignant Urinary System Neoplasm Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells Drug: Cyclophosphamide Drug: Etoposide Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the safety, maximum tolerated dose and/or recommended phase II dose of cord blood-derived expanded allogeneic natural killer cells (expanded allogeneic cord donor natural killer [NK] cells) following chemotherapy.

SECONDARY OBJECTIVES:

I. Determine the persistence of adoptively-transferred cord NK cells after solid tumor directed chemotherapy.

II. Preliminarily define the antitumor activity to adoptively transferred NK cells following the study preparative regimen in the confines of a phase I study.

III. Determine the immunophenotype and function of the infused NK cell product. IV. Preliminarily evaluate for any correlate of phenotype, killer cell immunoglobulin-like receptor (kir) haplotype, and function with overall response.

OUTLINE: This is a dose escalation study of cord blood derived allogeneic NK cells.

Patients receive cyclophosphamide intravenously (IV) once daily (QD) over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.

After completion of study treatment, patients are followed up at 3-4 days, and then every week for 30 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults
Actual Study Start Date : August 31, 2018
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : December 1, 2022


Arm Intervention/treatment
Experimental: Treatment (cyclophosphamide, etoposide, NK cells)
Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Given IV
Other Names:
  • Allogeneic CB-derived Ex vivo-expanded NK Cells
  • CB-derived Expanded Allogeneic NK Cells
  • UCB-derived Expanded Allogeneic NK Cells
  • Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells

Drug: Cyclophosphamide
Given IV
Other Names:
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CTX
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Cytoxan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719

Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Up to 30 days after the NK cell infusion ]
    Since toxicity is the primary outcome, patients with non-measurable disease (who are still evaluable) will be included in the analysis and in these cases standard methods for categorizing response of non-measurable disease will be used. Toxicity rate will be estimated separately by dose and cohort along with a 95% confidence interval. Adverse events will be tabulated for all the patients separately by dose levels.

  2. Maximum tolerated dose and/or recommended phase 2 dose of cord blood-derived expanded allogeneic natural killer (NK) cells following chemotherapy [ Time Frame: Up to 30 days after the NK cell infusion ]
    Primary analyses in this phase I trial are descriptive and exploratory. Toxicity rate will be estimated separately by dose and cohort along with a 95% confidence interval. Adverse events will be tabulated for all the patients separately by dose levels.


Secondary Outcome Measures :
  1. NK cell persistence, phenotype, and function [ Time Frame: Up to 30 days after the NK cell infusion ]
    Correlation of NK cell persistence, phenotype, and function with overall response will be estimated using two-sample t-test/Wilcoxon sum-rank test and ANOVA/Kruskal-Wallis test as appropriate.

  2. Response rate per immune-related therapy trials Response Evaluation Criteria in Solid Tumors (irRECIST) [ Time Frame: Up to 30 days after the NK cell infusion ]
    Complete response and partial response will be estimated separately by dose and cohort along with a 95% confidence interval. Correlation of NK cell persistence, phenotype, and function with overall response will be estimated using two-sample t-test/Wilcoxon sum-rank test and analysis of variance (ANOVA)/Kruskal-Wallis test as appropriate.

  3. Overall survival (OS) [ Time Frame: Up to 30 days after the NK cell infusion ]
    The Kaplan-Meier method will be used to estimate the distribution of OS. The description statistics of rate of OS may be analyzed separately by different tumor types and response/stable patients. Cox proportional hazards regression analysis may also be conducted to model the association between OS or TTP, and factors of interest.

  4. Time to progression (TTP) [ Time Frame: Up to 30 days after the NK cell infusion ]
    The Kaplan-Meier method will be used to estimate the distribution of TTP. The description statistics of rate of TTP may be analyzed separately by different tumor types and response/stable patients. Cox proportional hazards regression analysis may also be conducted to model the association between OS or TTP, and factors of interest.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • SCREENING: Patients with relapsed or refractory solid tumors and without known curative therapy or therapy proven to proven to prolong survival with acceptable quality of life.
  • SCREENING: Patients older than 21 years must have a solid tumor considered by study doctor to be of the childhood cancer type.
  • SCREENING: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
  • SCREENING: Documentation of measurable or evaluable non-measurable disease.
  • SCREENING: At least one documented histological verification of solid tumor diagnosis. Can be from original diagnosis or more recent.
  • ENROLLMENT: Patient must have fully recovered (i.e. returned to baseline) from the clinically significant acute treatment-related toxicities of all prior treatments prior to beginning treatment on this protocol with exceptions of cytopenias resulting from persistent disease, hearing loss and alopecia.
  • ENROLLMENT: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
  • ENROLLMENT: Creatinine clearance >= 60 mL/min/1.73m^2 (calculated by 24 hour [h] urine collection or nuclear glomerular filtration rate [GFR] scan if 24 h collection is not possible) or a serum creatinine based on age and gender as follows: age 1 month to < 6 months, maximum serum creatinine (mg/dL) male 0.4, female 0.4; 6 months to < 1 year, 0.5, 0.5; 1 to < 2 years, 0.6, 0.6; 2 to < 6 years, 0.8, 0.8; 6 to < 10 years, 1, 1; 10 to < 13 years, 1.2, 1.2; 13 to < 16 years, 1.5, 1.4; >= 16 years, 1.7, 1.4.
  • ENROLLMENT: Adequate liver function, defined as: total bilirubin =< 2 mg/dl
  • ENROLLMENT: Adequate liver function, as defined as serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x upper limit of normal (ULN) for age (unless Gilbert's disease or abnormal liver function due to primary disease).
  • ENROLLMENT: Evidence of adequate bone marrow function (defined by absolute neutrophil count >= 750), unless patient has documented tumor metastasis to the bone marrow or other condition that results in cytopenia without abnormal marrow function.
  • ENROLLMENT: Evidence of adequate bone marrow function (defined by platelets >= 50,000), unless patient has documented tumor metastasis to the bone marrow or other condition that results in cytopenia without abnormal marrow function.
  • ENROLLMENT: Pulmonary symptoms controlled by medication and pulse oximetry >= 92% on room air.
  • ENROLLMENT: Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the investigator. (Non-childbearing potential defined as pre-menarche, greater than one year post-menopausal or surgically sterilized).
  • ENROLLMENT: Confirmation that a cord blood donor which is matched with the recipient at a 4, 5, or 6/6 human leukocyte antigen (HLA) class I (serological) and HLA class II (molecular) antigens.
  • ENROLLMENT: Signed informed consent and if applicable pediatric assent.

Exclusion Criteria:

  • SCREENING: Primary tumors of the central nervous system.
  • SCREENING: Chronic corticosteroid dependence that is unable to be weaned to discontinue.
  • SCREENING: Determined by study doctor that patient is unlikely to meet inclusion criteria after screening.
  • ENROLLMENT: Uncontrolled arrhythmias or uncontrolled symptoms of cardiac disease noted by screening history and physical. Patients with known cardiac dysfunction should have an ejection fraction (EF) > 40% documented by echocardiogram (ECHO).
  • ENROLLMENT: Patients where the burden of pulmonary metastasis, location, or bulkiness of disease may cause high morbidity if localized swelling such as causing uncontrolled symptoms, oxygen dependence, or location near a major bronchi as determined by investigator.
  • ENROLLMENT: Pregnant females.
  • Any uncontrolled systemic infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03420963


Contacts
Layout table for location contacts
Contact: Jessica S. Foglesong, MD 713-792-6620 jsfoglesong@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Jessica A. Foglesong    713-792-6620      
Principal Investigator: Jessica A. Foglesong         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Jessica A Foglesong M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03420963     History of Changes
Other Study ID Numbers: 2017-0085
NCI-2018-00909 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2017-0085 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: February 2, 2018    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Skin Neoplasms
Bone Neoplasms
Genital Neoplasms, Female
Soft Tissue Neoplasms
Pharyngeal Neoplasms
Endocrine Gland Neoplasms
Mouth Neoplasms
Urologic Neoplasms
Genital Neoplasms, Male
Thyroid Neoplasms
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Urogenital Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Mouth Diseases
Neoplasms, Connective and Soft Tissue
Melanoma
Mesothelioma
Sarcoma